Recursion Pharmaceuticals, Inc. Class A (RXRX) Dividend History

Recursion Pharmaceuticals, Inc. Class A (RXRX) is a biotechnology company that leverages machine learning and automation to discover and develop new medicines. Founded with a focus on using data-driven approaches to accelerate drug discovery, Recursion combines high-throughput biology, AI, and computational science to identify potential therapeutic candidates across various diseases. The company aims to streamline the development process and improve success rates in bringing innovative treatments to market.

41s Rio Grande Street, Salt Lake City, UT, 84101
Phone: (385) 269-0203
Website:

Dividend History

Recursion Pharmaceuticals, Inc. Class A currently does not pay dividends

Company News

  • 3 Monster Stocks to Hold for the Next 10 Years

    The article discusses three stocks with high growth potential over the next 10 years: Intuitive Machines, NuScale Power, and Recursion Pharmaceuticals. Intuitive Machines is poised to benefit from upcoming NASA moon missions, NuScale Power offers a solution to the electricity demands of AI data centers, and Recursion Pharmaceuticals is using AI to accelerate drug development.

    The Motley Fool
    Featured Companies: LUNR SMR
  • Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?

    Recursion Pharmaceuticals, an AI-focused biotech company, has attracted attention from investors like Cathie Wood, but its stock has fallen 35% this year. The company is facing challenges, including abandoning some drug candidates and potential funding issues. While it has a strong cash position and partnerships with leading drugmakers, it remains a high-risk option as it has yet to advance a single drug to phase 3 trials.

    The Motley Fool
  • Why Recursion Pharmaceuticals Stock Plummeted 24% This Week

    Recursion Pharmaceuticals reported disappointing Q1 earnings and announced it would pare down its development pipeline. The biotech industry also expects President Trump's federal research cuts to make raising capital more challenging, which negatively impacted Recursion and other biotech stocks.

    The Motley Fool
    Featured Companies: CRSP SMMT
  • Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

    Recursion's investigational drug REC-4881 showed a median 43% reduction in polyp burden in a Phase 2 study for Familial Adenomatous Polyposis (FAP), a rare genetic disorder. The early safety profile was generally consistent with prior MEK1/2 inhibitors.

    GlobeNewswire Inc.
  • Why Biohaven Stock Plummeted by More Than 15% Today

    Biohaven, a clinical-stage biotech company, withdrew its application for a drug candidate in Europe, leading to a significant drop in its stock price. The European Medicines Agency cited several issues that mitigated against approval, and Biohaven plans to generate additional data to support a new application.

    The Motley Fool
    Featured Companies: BHVN
Dividend data last updated 06/07/2025 07:40:39 UTC